Market closed
Geron/$GERN
Geron shares are trading lower following multiple announcements of class action lawsuits against the company for alleged securities law violations.
5 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Geron
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Ticker
$GERN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
229
Website
Geron Metrics
BasicAdvanced
$1B
-
-$0.27
0.53
-
Price and volume
Market cap
$1B
Beta
0.53
52-week high
$5.34
52-week low
$1.45
Average daily volume
19M
Financial strength
Current ratio
5.561
Quick ratio
5.044
Long term debt to equity
43.073
Total debt to equity
43.42
Interest coverage (TTM)
-9.39%
Management effectiveness
Return on assets (TTM)
-21.98%
Return on equity (TTM)
-66.09%
Valuation
Price to revenue (TTM)
13.341
Price to book
3.77
Price to tangible book (TTM)
3.77
Price to free cash flow (TTM)
-4.684
Growth
Revenue change (TTM)
32,386.92%
Earnings per share change (TTM)
-16.25%
3-year revenue growth (CAGR)
280.92%
3-year earnings per share growth (CAGR)
-8.64%
What the Analysts think about Geron
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Geron Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Geron Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Geron News
AllArticlesVideos
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit - GERN
Accesswire·7 minutes ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Corporation Lawsuit - GERN
Accesswire·37 minutes ago
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN
GlobeNewsWire·37 minutes ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Geron stock?
Geron (GERN) has a market cap of $1B as of April 03, 2025.
What is the P/E ratio for Geron stock?
The price to earnings (P/E) ratio for Geron (GERN) stock is 0 as of April 03, 2025.
Does Geron stock pay dividends?
No, Geron (GERN) stock does not pay dividends to its shareholders as of April 03, 2025.
When is the next Geron dividend payment date?
Geron (GERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Geron?
Geron (GERN) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.